Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. - Wikidata - awgldk - TriplyDB

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

http://www.wikidata.org/entity/Q45361995

about

Management of HBV and HBV/HDV-Associated Liver Cirrhosis Current and future directions for treating hepatitis B virus infection Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Alpha-interferon treatment in hepatitis B Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir.Chronic hepatitis B: Advances in treatment.A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Strategies to eliminate HBV infection.AASLD guidelines for treatment of chronic hepatitis B.CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.Hepatitis B virus genotypes and variants.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection.Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study The role of HBsAg quantification for monitoring natural history and treatment outcome.Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.Expert recommendations on the application of interferon for chronic hepatitis B.Peginterferon α in the treatment of chronic hepatitis B.Improving clinical outcomes of chronic hepatitis B virus infection.Update on hepatitis B virus infection.Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies.Treating Immune-tolerant Hepatitis B.Monotherapy for hepatitis B infection: a review of treatment options.Pharmacotherapeutic options for hepatitis B.

P2860

Q26740323-3EAC88E9-3154-4384-B125-797FBBF13B03 Q26851240-94CA7681-35EB-4D43-9B9E-5849E3F36497 Q26865747-4CB48C9D-3BCB-440E-8E88-96C636ABDBCA Q26995814-09128D7D-F1BE-4A86-B61C-4D8D81124658 Q27008984-E6461052-263C-4ED8-9F25-EEF770F1EACD Q30391932-93E97A32-132C-475E-9910-85541CDE5DC6 Q33592755-8D30CE77-E85F-481F-9AD9-B01B1EA5022D Q33604145-742EC3F7-EA30-446D-B89E-43F10895AA09 Q33660010-94E82822-33A2-448D-8679-3B019C93314D Q33773772-293BEB4B-3021-4654-B93D-9C328DFA9658 Q34137291-4C20CBF1-72EE-4BC7-8419-DF3F27C95C65 Q34308129-9018B19E-6385-4925-BD1E-A69AA82CFADE Q34501660-D25B4F01-77C4-4AA3-81CA-BDFABB9441A9 Q35017075-7269C469-F32E-490C-9A1B-27BE5C10D4A6 Q35118955-CEE1EC70-A007-438B-9B97-BA03D772E5BC Q35250340-86CFD446-1517-44BE-B8E5-C81AF5D9D3F9 Q35663838-A0C4089A-855D-4CB7-BB62-8183824568E0 Q35688409-5D5B64AA-00EF-454D-97CC-CD2BE61670E2 Q36401963-C9E8033A-2A2E-4C8E-A34E-0DB34133B925 Q36457659-BB502718-9C8E-4D70-AB6B-465575DC4BDF Q36577343-FDD6CEB7-2A23-41DA-A273-0CF2AC73BBFA Q36713419-79D55FAA-592C-43D8-BB54-0BCB762AE2A4 Q36805368-3E71DF24-F980-4B9C-A122-A96394B76439 Q36924978-7F5580C1-58AB-4F68-9724-B3CD284A93D4 Q36954595-36679BCF-6791-41DA-B9E7-01F66797E96B Q36973383-6F203C33-8C48-4C6D-B4FC-67F8474D5AFC Q37087279-D2A9C756-DD24-43A1-9393-87772D90C7B0 Q37165176-B3CF4E1C-7410-4A02-947C-36DAD16D1FBD Q37206545-58A66D1A-45E7-47A2-BC9E-AF097FA78604 Q38071397-E4293D4C-2267-4DA2-9BFE-86B56788105A Q38071399-4B009218-71A6-4863-9CF0-FA262D734BB8 Q38102776-4FA9525A-E0CD-4BAE-B455-BB730E3CE99D Q38131868-25E8902C-E17E-4DE9-8AD0-8AE3B00139A2 Q38205028-40AF117C-5EA2-4AF7-A4C3-9B658E2370C5 Q38252962-3D984DAC-891D-4D3E-9EA6-6BE88FE9A4AB Q38259535-4FA7597E-B9D8-4528-A8ED-044A8CFD240C Q38265395-1D6FBF94-FCF1-4707-8215-1701BC8824D6 Q38271430-339AB7E6-C170-4792-AC86-C4313CFCCAE0 Q38594605-063C9DD7-9528-4D14-9C27-5CF2A2902F53 Q38631076-0D0166A8-994B-441F-9896-7A5AC9ADDD5A

P2860

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

http://www.wikidata.org/entity/Q45361995

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Shorter durations and lower do ...... itis B virus genotypes B or C.

@en

Shorter durations and lower do ...... itis B virus genotypes B or C.

@nl

type

label

Shorter durations and lower do ...... itis B virus genotypes B or C.

@en

Shorter durations and lower do ...... itis B virus genotypes B or C.

@nl

prefLabel

Shorter durations and lower do ...... itis B virus genotypes B or C.

@en

Shorter durations and lower do ...... itis B virus genotypes B or C.

@nl

P1433

Q45361995-7E3A4A10-331C-4B2D-9967-3A6B269CB635

P1476

Q45361995-46DF9C69-9B83-46D4-A599-0710EF48FD7B

P2093

Q45361995-0352C61B-0B60-4CD6-B4FD-0D42D0C805CA

Q45361995-65138089-4319-4F0C-8E0D-DF4D7740DDC2

Q45361995-683C4580-0B9E-4F75-A0BC-E4D63C000406

Q45361995-743C6F76-BB22-4DB5-ABF0-9F4D7081F05B

Q45361995-7E78963E-BD31-49B4-8090-59D7FAE69131

Q45361995-8FE28B28-25CD-435E-931A-78F35E40CF1C

Q45361995-91D79AD1-0B8D-4652-90CF-350D20055F2F

Q45361995-9912093E-81C3-4A61-8D85-ED6633588445

Q45361995-A88B05DE-0288-45C9-A1BC-09486BE624DD

Q45361995-B65FE396-5BD2-492D-B2B0-C9EF21203822

P2860

Q45361995-12E72442-A521-4A96-9DA3-6EBCBE84539A

Q45361995-27D6BF1E-B36E-4C11-9C94-BFEE62C5E3D0

Q45361995-337A7A5D-CFF6-4CB4-B2CB-BAE26E874440

Q45361995-4634750F-4176-4B6A-BCD5-2D9394770414

Q45361995-49EDD2ED-D322-4F67-A06B-BCA51B6516CB

Q45361995-4BF6C2C8-6745-4820-9E12-A8555DDBAC2B

Q45361995-4D2214C8-8BE1-4062-B738-1E49DE65F095

Q45361995-7CF560F7-9A06-40C3-8B3C-AB9EAE8B15AA

Q45361995-BE1B321E-FE49-43AA-B386-BAA8D5F4A8B3

Q45361995-F3CEDBE6-6816-4109-A613-4EAC06DE167D

P304

Q45361995-F38731A9-CA1A-4259-AFA5-F95EAD19C67D

P31

Q45361995-A81A4AAE-0337-405A-BAF3-E73AE7690BC9

P356

Q45361995-D004DD50-737C-4874-A603-B4220240F1C6

P407

Q45361995-97FD46E9-D809-4D9F-8228-FD922549E3E3

P433

Q45361995-03977981-6CA5-4843-8086-10D2EE309FFA

P478

Q45361995-6B1EFBD7-B22D-4E22-AE20-95AEA242DF3F

P50

Q45361995-D3B9CDD7-CD54-41DD-AEB0-84B42C508EE8

P577

Q45361995-774A4BA5-FD21-4840-81A6-D6AEC93B8B40

P5875

Q45361995-48740430-64C0-493C-B8C7-3410F73560D5

P698

Q45361995-A8DC2741-623A-4489-9059-E1E1F3F21249

P921

Q45361995-78380271-2B26-49CD-9137-DE83D540CD64

P356

P1433

P1476

Shorter durations and lower do ...... titis B virus genotypes B or C

@en

P2093

C Bernaards

http://www.w3.org/2001/XMLSchema#string

C Wat

http://www.w3.org/2001/XMLSchema#string

D M Tan

http://www.w3.org/2001/XMLSchema#string

E Gane

http://www.w3.org/2001/XMLSchema#string

H L Y Chan

http://www.w3.org/2001/XMLSchema#string

J-D Jia

http://www.w3.org/2001/XMLSchema#string

K H Han

http://www.w3.org/2001/XMLSchema#string

L Chen

http://www.w3.org/2001/XMLSchema#string

P Marcellin

http://www.w3.org/2001/XMLSchema#string

Q Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Chronic hepatitis B: update 2009

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

P304

1591-1599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.24555

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Joseph J Y Sung

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51763361

http://www.w3.org/2001/XMLSchema#string

P698

22045673

http://www.w3.org/2001/XMLSchema#string

P921